Signs there is a problem with your prostate

by Jason HowlandProstate cancer cells. Credit: NIH Image GalleryNovember is the time of the Movember movement, which encourages growing a mustache during the month to raise awareness of men's heal

Updated on: February 20,2024

Signs there is a problem with your prostate

by Jason HowlandProstate cancer cells. Credit: NIH Image GalleryNovember is the time of the Movember movement, which encourages growing a mustache during the month to raise awareness of men's heal

Updated on:February 20,2024

Cancer patients who don't respond to immunotherapy may lack crucial immune cells

byWashington University School of MedicineCD5+ DC frequency was reduced in tumor-affected lymph nodes, and their presence correlated with greater patient survival in multiple tumors. CD5+D

Updated on: December 20,2023

Cancer patients who don't respond to immunotherapy may lack crucial immune cells

byWashington University School of MedicineCD5+ DC frequency was reduced in tumor-affected lymph nodes, and their presence correlated with greater patient survival in multiple tumors. CD5+D

Updated on:December 20,2023

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024

Study shows clinical benefit of a new way of treating advanced ER+ breast cancer

by University of LiverpoolCredit: Unsplash/CC0 Public DomainA research paper published today inThe Lancet Oncologydemonstrates that the drug enobosarm, a selective androgen receptor m

Updated on: May 26,2024

Study shows clinical benefit of a new way of treating advanced ER+ breast cancer

by University of LiverpoolCredit: Unsplash/CC0 Public DomainA research paper published today inThe Lancet Oncologydemonstrates that the drug enobosarm, a selective androgen receptor m

Updated on:May 26,2024

New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on: December 22,2023

New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on:December 22,2023

Could artificial sweeteners alter your microbiome?

by Dennis ThompsonYou may think that artificial sweeteners can help you lose some weight, but a new study finds they are no good for your gut's microbiome.People who useaspartame(Equal

Updated on: May 06,2024

Could artificial sweeteners alter your microbiome?

by Dennis ThompsonYou may think that artificial sweeteners can help you lose some weight, but a new study finds they are no good for your gut's microbiome.People who useaspartame(Equal

Updated on:May 06,2024

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on: July 11,2024

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on:July 11,2024

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve

Updated on: February 20,2024

Researchers identify protein with DYRK1A-inhibiting effect that may have implications for Down syndrome

by Kyoto UniversityDYRK1A bound to FAM53C in the cytoplasm is less active. DYRK1A not bound to FAM53C in the nucleus is highly active. Functional abnormalities cause various neuropsychiatric deve

Updated on:February 20,2024

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th

Updated on: January 05,2024

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th

Updated on:January 05,2024

Racial disparities in lung cancer start with research

by Melba NewsomeCredit: Pixabay/CC0 Public DomainDuring a routine visit to the Good Samaritan Clinic in Morganton, North Carolina, in 2018, Herbert Buff casually mentioned that he sometimes had troubl

Updated on: December 22,2023

Racial disparities in lung cancer start with research

by Melba NewsomeCredit: Pixabay/CC0 Public DomainDuring a routine visit to the Good Samaritan Clinic in Morganton, North Carolina, in 2018, Herbert Buff casually mentioned that he sometimes had troubl

Updated on:December 22,2023

How do we overcome treatment resistance in a sarcoma cancer with already limited treatment options?

by Elena Daviter-Nowell,Institute of Cancer ResearchHistopathology image of leiomyosarcoma. Credit:Wikimedia Commons, CC-BY-SA 4.0Leiomyosarcoma is a type of soft tissue sarcoma that is ha

Updated on: January 10,2024

How do we overcome treatment resistance in a sarcoma cancer with already limited treatment options?

by Elena Daviter-Nowell,Institute of Cancer ResearchHistopathology image of leiomyosarcoma. Credit:Wikimedia Commons, CC-BY-SA 4.0Leiomyosarcoma is a type of soft tissue sarcoma that is ha

Updated on:January 10,2024

Disorderly DNA helps cancer cells evade treatment

byNorthwestern UniversityWhen the chromatin packing is heterogenous and disordered, a cell demonstrates more plasticity. Credit: Northwestern UniversityEach cell in the human body holds a full t

Updated on: December 22,2023

Disorderly DNA helps cancer cells evade treatment

byNorthwestern UniversityWhen the chromatin packing is heterogenous and disordered, a cell demonstrates more plasticity. Credit: Northwestern UniversityEach cell in the human body holds a full t

Updated on:December 22,2023